CWM
DFTX

CarsonAllaria Wealth Management’s Definium Therapeutics DFTX Stock Holding History

CarsonAllaria Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-325
Closed -$2.11K – 235
2025
Q2 		$2.11K Hold
325
– – ﹤0.01% 317
2025
Q1 		$1.9K Buy
+325
New +$2.33K ﹤0.01% 326
2023
Q1 		– Sell
-3
Closed – – 379
2022
Q4 		$0 Buy
+3
New +$8 ﹤0.01% 356

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CarsonAllaria Wealth Management's DFTX Position: Q3 2025 in Review

CarsonAllaria Wealth Management sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 325 shares — an estimated $2.11K sold.

CarsonAllaria Wealth Management first reported a position in DFTX in Q4 2022 and held it in 3 quarters. The position peaked at $2.11K in Q2 2025. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

  • CarsonAllaria Wealth Management reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
  • CarsonAllaria Wealth Management sold 325 Definium Therapeutics shares in Q3 2025, an estimated $2.11K.
  • CarsonAllaria Wealth Management first reported a position in Definium Therapeutics in Q4 2022 and held it in 3 quarters.
  • CarsonAllaria Wealth Management's Definium Therapeutics position peaked at $2.11K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2025, filed 28 Oct 2025.